`
`
`12015 Surrey Lane, Houston, TX 77024
`September 20, 1962
`United States
`
`
`2009‐to‐Present
`
`2009‐to‐Present
`
`2009‐to‐2014
`
`
`2001‐to‐2008
`
`2000‐to‐2008
`
`1999‐to‐2008
`
`University of California ― Davis, Davis, CA
`B.S. ― Biochemistry & Biophysics
`Baylor College of Medicine, Houston, TX
`Ph.D. ― Molecular & Human Gene(cid:415)cs
`
`I. General Biographical Information
`a. Personal:
`Home address:
`Date of birth:
`Citizenship:
`
`b. Education:
`1984
`
`1996
`
`
`c. Academic Appointments:
`2014‐to‐Present
`Adjunct Associate Professor, Department of Molecular & Human
`Genetics & Human Genome Sequencing Center,
`Baylor College of Medicine, Houston, TX
`Adjunct Associate Professor, Cell & Molecular Biology,
`Baylor College of Medicine, Houston, TX
`Adjunct Associate Professor, Department of Chemistry,
`Rice University, Houston, TX
`Associate Professor, Department of Molecular & Human Genetics &
`Human Genome Sequencing Center,
`Baylor College of Medicine, Houston, TX
`Adjunct Assistant Professor, Department of Chemistry,
`Rice University, Houston, TX
`Adjunct Assistant Professor, Cell & Molecular Biology,
`Baylor College of Medicine, Houston, TX
`Assistant Professor, Department of Molecular & Human Genetics &
`Human Genome Sequencing Center,
`Baylor College of Medicine, Houston, TX
`
`
`
`d. Corporate positions and other professional experiences:
`2013‐to‐Present
`Founder, President & CEO, RedVault Biosciences, Houston TX
`2012
`Founder, CTO, LaserGen, Inc.
`2009
`Appeared on ABC’s 20/20 profiling Collin Co. HIV criminal case
`2009
`Collin Co. work appeared on Oprah
`2007‐to‐2009
`Expert witness for HIV criminal case, Collins Co., TX
`2004
`Expert witness for HIV criminal case, Thurston Co., WA
`2003
`Appeared on truTV’s series Forensics Files in episode #152,
`
`“Shot of Vengeance”
`2002‐to‐2012
`Founder, President & CEO, LaserGen, Inc., Houston TX
`1997‐to‐1999
`Expert witness for HIV criminal case, Lafayette, LA
`1996‐to‐1999
`Senior Research Biologist, Merck Research Laboratories, West Point, PA
`1987‐to‐1991
`Associate Scientist, Applied Biosystems, Inc. (ABI), Foster City, CA
`1984‐to‐1987
`Research Chemist, Bio‐Rad Laboratories; Richmond, CA
`
`1
`
`MYR 1003
`Myriad Genetics, Inc. et al. (Petitioners) v. The Johns Hopkins University (Patent Owner)
`IPR For USPN 7,824,889
`
`Page 1 of 18
`
`
`
`
`
`
`
`Laboratory Technician, Aerojet‐General Corporation; Sacramento, CA
`1983‐to‐1984
`e. Prior Expert Experience
`In the past four years, I have provided expert testimony at trial or deposition in the following
`cases:
`
`
`Life Technologies, Inc. v. Illumina, Inc., C.A. No. 11‐cv‐00703‐CAB (on behalf of Life
`Technologies)
` Syntrix Biosciences, Inc. v. Illumina, Inc., C.A. No. 3:10‐cv‐05870‐BHS (on behalf of Syntrix
`Biosciences)
` Ariosa Diagnostics, Inc. v. Sequenom, Inc., C.A. No. 3:11‐cv‐06391‐SI (on behalf of
`Sequenom)
` Verinata Health, Inc. v. Sequenom, Inc., C.A. No. 3:12‐cv‐00865‐SI (on behalf of
`Sequenom)
` Esoterix Genetic Laboratories, LLC and The Johns Hopkins University v. Life Technologies,
`N.C. No. 1:12‐cv‐1173 (on behalf of Life Technologies)
`Intelligent Biosciences, Inc. vs. Illumina Cambridge, Ltd, IPR2013‐00517 (on behalf of
`Intelligent Biosciences)
` Scot E. Dowd, individually, and, Molecular Research, LP d/b/a (MR DNA) v. Research &
`Testing Laboratory of the South Plains, LLC (RTL). No. 5:13‐CV‐248‐C (on behalf of RTL)
`Joseph A. Sorge v. Eric H. Kawashima al., Patent Interference Nos. 106,109 & 106,020 (on
`behalf of Sorge)
` Wellbeing Genomics v. Dr. Harper, Mr. Urman, PLLG, and Qivana, D‐1‐G‐14‐002452 (on
`behalf of Wellbeing Genomics)
`Intelligent Biosciences, Inc. vs. Illumina Cambridge, Ltd, 3:16‐cv‐02788‐WHA (on behalf of
`Intelligent Biosciences)
`Irori Technologies v. Procopio, Cory, Hargreaves & Savitch LLP, and Eleanor M. Musick,
`JAMS Ref No. 1240022033 (on behalf of Procopio)
`II. Research Information
`a. Research Support
`1 ― Current research support
`Technical description: The research proposed here is oriented toward significantly improving
`the methods of sample preparation, which will lead to improved efficiency, accuracy, and
`reduced costs to sequence DNA.
`Funding agency: NIH/NCI
`Investigator relationship: PI: Michael Metzker; co‐PI: Chris Weier
`Date of funding: 01/14/2016 – 11/13/2016
`Annual costs: $146,801
`Grant: R43 CA196134‐01A1, entitled, “Efficient Creation of Long‐Template Libraries for Next‐
`Generation Sequencing”
`
`Technical description: Leveraging advanced molecular genomics technology and novel nucleic‐
`acid detection methods, RedVault Biosciences’ proposes an innovative approach to reliably
`interrogate plasma specimens for clinically relevant miRNAs. The methodology is a robust,
`
`
`
`
`
`2
`
`Page 2 of 18
`
`
`
`rapid, specific, sensitive and cost‐effective solution that meets the stringent criteria laid out for
`effective diagnostic platforms. Successful development of this technology may deliver a
`fundamental advancement in the cancer screening, tumor surveillance, and miRNA research
`fields.
`Funding agency: NIH/NCI
`Investigator relationship: PI: Chris Weier; co‐PI: Michael Metzker
`Date of funding: 04/01/2016 – 12/31/2016
`Annual costs: $150,000
`Grant: R43 CA200398‐01A1, entitled “Homogenous digital RCR analysis of plasma miRNAs in
`pancreatic cancer”
`
` ― Pending research support
`Technical description: The demand for robust, reliable, and minimally invasive diagnostic
`technologies represents a pressing need in the early detection, stratification, and surveillance of
`microvascular complications in Type 1 diabetes (T1D). Cell‐free microRNAs (miRNAs) represent
`a novel class of biomarkers that have shown promise during initial studies and may have
`significant clinical utility. RedVault Biosciences proposes to establish the feasibility of a novel
`multiplex diagnostic platform to precisely characterize cell‐free miRNA signatures, specifically
`those miRNAs of immediate utility in diagnosis, stratification, and intervention in T1D
`microvascular complications.
`Funding agency: NIH/NIDDK
`Investigator relationship: PI: Chris Weier; co‐PI: Michael Metzker
`Date of funding: 12/01/2016 – 08/31/2017
`Annual costs: $225,000
`Grant: R43 DK112501‐01, entitled “Non‐invasive resolution of miRNAs signatures in Type 1
`diabetes”
`
` 2
`
` 3
`
` ― Completed research support:
`Technical description: The major goals of this project are to support sequencing and technology
`development in the areas of human genetics, cancer, the microbiome and comparative genomics.
`Funding agency: NIH/NHGRI
`Investigator relationship: Richard A. Gibbs; Co‐Director Boerwinkle; co‐PIs Muzny, Wheeler,
`Metzker, Worley
`Date of funding: 11/01/2011 – 02/08/2015; effective end 02/08/14
`Annual costs: $20,119,270
`Grant: U54 HG003273‐09, entitled, ”The Human Genome Sequencing Center”
`Technical description: This proposal represents a request for continued funding of the Mayo Clinic
`Pharmacogenomics Research Network (PGRN) grant, “Pharmacogenetics of Phase II Drug
`Metabolizing Enzymes.” The Mayo PGRN is an integrated, multidisciplinary, pharmacogenomic
`research effort that is based on a decades‐long focus at Mayo on the pharmacogenetics of phase
`II (conjugating) drug metabolizing enzymes.
`Funding agencies: NIGMS, NHLBI, NCI, NIDA, NICHD, NHGRI, NIMH, NIAMS, ORWH
`Investigator relationship: Richard Weinshilboum; Co‐PIs Gibbs, Metzker, Scherer
`Date of funding: 7/01/10 to 06/30/15; effective end 02/08/14
`Annual costs: $425,709
`Grant: 2U19GM061388‐12, entitled “Pharmacogenetics of Phase II Drug Metabolizing Enzymes”
`
`3
`
`Page 3 of 18
`
`
`
`Technical description: This proposal seeks to expand our existing scientific work on HIV forensic
`studies by developing a robust ‘pathogen toolkit’ for source identification across a range of
`biological agents
`Funding agencies: National Institute of Justice
`Investigator: Michael L. Metzker
`Date of funding: 01/01/12 to 12/31/13
`Annual costs: $341,017
`Grant: 2011‐DN‐BX‐K534 entitled, “Extending the Microbial Forensic Toolkit Through Whole
`Genome Sequencing and Statistical Phylogenomics”
`Technical description: This Phase I SBIR grant application proposes three aims: (i) identify the
`most efficient NGS platform by sequencing E. coli MG1655 using six platforms, (ii), conduct
`mixing experiments using purified gram negative and gram positive bacteria using the platform
`selected in aim (i), and (iii) conduct mixing experiments described in aim (ii) in the presence of
`human blood to simulate animal wound models.
`Funding agency: Office of the Secretary of Defense, Defense Health Program
`Investigator relationship: David Hertzog; co‐PI Metzker
`Date of funding: 02/01/11 to 08/31/12
`Total costs: $150,000
`Annual costs: $150,000
`Contract: W81XWH‐12‐C‐0061, entitled “Feasibility Study to Explore NGS Technologies in
`Pathogen Identification”
`Technical description: The goal is to evaluate the feasibility of our next‐generation, cyclic
`reversible termination (CRT) sequencing approach by targeting 1,000 candidate genes on high‐
`density oligonucleotide chips.
`Funding agency: NIH: NHGRI
`Investigator: Michael L. Metzker
`Date of funding: 08/01/08 to 05/31/11
`Total costs: $422,125
`Annual costs: $230,250
`Grant: 1R21 HG004757, entitled “Targeted CRT Sequencing of 1000 Genes in KPD Patients”
`Technical description: The goal is to develop ultrafast sequencing‐by‐synthesis (SBS) technology
`that is practical on a genomic scale.
`Funding agency: NIH: NHGRI
`Investigator: Michael L. Metzker
`Date of funding: 10/01/04 to 09/30/08
`Total costs: $2,933,762
`Annual costs: $468,575
`Grant: 1 R01 HG003573‐01 entitled, “Ultrafast SBS Method for large‐Scale Human
`Resequencing”
`Technical description: Development of a novel portable DNA sequencer for rapid identification of
`single nucleotide polymorphisms (SNPs) in common disease.
`Funding agency: NIH: NHGRI
`Investigator: Michael L. Metzker
`Date of funding: 06/07/04 to 02/28/06
`Total costs: $532,761
`Annual costs: $421,914
`Grant: 1 R41 HG003265‐01 entitled, “Development of a Portable PME DNA Sequencer”
`Technical description: Development of novel FluoroBase dyes and associated nucleotide
`triphosphates, which have the potential to create sets of spectrally resolvable dye‐terminators.
`
`4
`
`Page 4 of 18
`
`
`
`Special note: Originally awarded to Michael L. Metzker as STTR application: Grant converted in
`SBIR
`Funding agency: NIH:NHGRI
`Investigator relationship: Vladislav A. Litosh; co‐PI Metzker
`Date of funding: 07/11/03 to 12/31/05
`Total direct costs: $289,689
`Annual costs: $213,064
`Grant: 1 R43 HG002632‐01A1 entitled, “Synthesis of FluoroBase Nucleotides for DNA Sequencing”
`Technical description: The major goal of this project is to produce a draft sequence of the rhesus
`macaque and bovine genomes and extract maximal biological information from these data.
`Funding agency: NIH: NHGRI
`Investigator relationship: Richard A. Gibbs; co‐Director Weinstock, co‐PIs Muzny, Wheeler,
`Metzker, Worley
`Date of funding: 11/10/03 to 10/31/06
`Total direct costs: $89,072,698
`Annual direct costs: $21,028,110
`Grant: 1 U01 HG02051 entitled, “Large Scale Sequencing at BCM‐HGSC”
`Technical description: The goal of this project is to generate a draft sequence of the genome of
`Bos Taurus.
`Funding agency: USDA
`Investigator relationship: Richard A. Gibbs; co‐Director Weinstock, co‐PIs Muzny, Wheeler,
`Metzker, Worley
`Date of funding: 12/01/03 to 11/31/05
`Total direct costs: $7,853,612
`Annual direct costs: $3,879,953
`Grant: TEXR‐2003‐05478 entitled, “Bovine Genome Sequencing Project (BGSP)”
`Technical description: Development of a novel multi‐color fluorescent detection apparatus with
`potential application for direct detection of targeted regions from genomic DNA materials.
`Funding agency: NIH: NHGRI
`Investigator: Michael L. Metzker
`Date of funding: 04/01/03 to 03/31/05
`Total costs: $250,000
`Annual costs: $150,000
`Grant: 1 R21 HG002443‐01A2, entitled “Development of Fluorescent Detector for DNA
`Sequencing”
`Technical description: Development of a novel DNA sequencing strategy by synthesis for
`application in high‐throughput single nucleotide polymorphism (SNP) analysis.
`Funding agency: NIH: NHGRI
`Investigator: Michael L. Metzker
`Date of funding: 09/30/03 to 03/31/05
`Total costs: $436,400
`Annual costs: $310,504
`Grant: 1 R41 HG003072‐01 entitled, “Screening Taq Pol I Variants using 3'‐O‐Modified‐dNTPs”
`Technical description: Pilot project to synthesize and characterize modified nucleoside for
`potential activity against HIV‐1.
`Funding agency: Robert A. Welch Foundation
`Investigator: Michael L. Metzker
`Date of funding: 06/01/01 to 07/31/04
`Total costs: $158,000
`Annual costs: $50,000
`Grant: Q‐1518 entitled, “Characterization of HIV‐1 drug resistance using 3’‐saturated nucleotides”
`
`5
`
`Page 5 of 18
`
`
`
`Technical description: Development of sixteen spectrally‐resolved dyes for high‐throughput
`nucleic acid detection such as DNA sequencing.
`Funding agency: NIH: NHGRI
`Investigator relationship: Mathew Mahindaratne; co‐PI Metzker – special note: Originally
`awarded to Michael L. Metzker as STTR application and then was converted in SBIR.
`Date of funding: 07/21/03 to 06/30/05
`Total direct costs: $214,000
`Annual direct costs: $214,000
`Grant: 1 R43 HG002567‐01A2 entitled, “Development of Novel Fluorescent Dyes for DNA
`Sequencing”
`Technical description: The major goal of this project is to determine the genome sequence of the
`rat.
`Funding agency: NIH: NHGRI/NHLBI
`Investigator relationship: Richard A. Gibbs; co‐Director Weinstock, co‐PIs Muzny, Wheeler,
`Metzker, Worley
`Date of funding: 02/27/01 to 02/26/04
`Total direct costs: $25,950,547
`Annual direct costs: $10,976,914
`Grant: 1 U54 HG02345‐02 entitled, “Draft sequence of the rat genome”
`Technical description: The major goal of this project is to prepare two types of extremely sensitive
`fluorescent label “cassettes” for DNA sequencing that may be used with both dye primer and dye
`terminator strategies.
`Funding agency: NIH: NHGRI
`Investigator relationship: Kevin Burgess; co‐PI Metzker
`Date of funding: 09/06/01 to 07/31/05
`Total direct costs: $114,923
`Annual direct costs: $38,296
`Grant: Competing Renewal FDN‐S80093 entitled, “Unnatural nucleotides for DNA sequencing”
`Technical description: To develop and validate novel pooling‐based methods for the rapid physical
`mapping of BAC libraries.
`Funding agency: NIH: NCRR
`Investigator relationship: Aleksandar Milosavljevic; co‐PI Metzker
`Date of funding: 09/30/02 to 08/31/05
`Total direct costs: $612,721
`Annual direct costs: $206,693
`Grant: 1 U01 RR18464‐01 entitled, “Clone pooling methods for physical mapping”
`Technical description: The major goals of this project are extensive mapping and sequencing of
`the mouse genome.
`Funding agency: NIH: NHGRI
`Investigator relationship: Richard A. Gibbs; co‐Director Weinstock, co‐PIs Muzny, Wheeler,
`Metzker, Worley
`Date of funding: 09/30/99 to 09/30/03
`Total direct costs: $20,851,198
`Annual direct costs: $5,316,551
`Grant: 1 U54 HG02139 entitled, “Network for large‐scale sequencing of the mouse genome”
`Technical description: To produce a draft sequence of D. pseudoobscura with annotation and
`finishing of selected full‐length cDNA and gene‐rich regions.
`Funding agency: NIH: NHGRI
`Investigator relationship: Richard A. Gibbs; co‐Director Weinstock, co‐PIs Richards, Muzny,
`Wheeler, Metzker, Worley
`Date of funding: 05/10/02 to 04/30/03
`
`6
`
`Page 6 of 18
`
`
`
`Total direct costs: $3,336,210
`Annual direct costs: $3,336,210
`Grant: 1 U01HG02570 entitled, “Sequencing, annotation and assembly of a second Drosophila”
`
`b. National Scientific Participation
`1 ― Editorial/Advisory Boards:
`2003‐to‐2006
`Genome Research, Cold Spring Harbor Laboratory Press
`2006‐to‐2012
`Advances in Genome Biology & Technology Meeting, Scientific advisor
`2007‐to‐present
`Milestones in DNA Technologies, Nature, Scientific advisor
`2011‐to‐2013
`Genome Canada: Advancing Technology Innovation through Discovery
`(ATID) Advisory Committee
`
`Sequencing Technology Special Emphasis Panel, ZHG1 HGR‐N (M1)
`Disruptive Innovation in Genomics (DIG) Competition, Genome Canada
`Chair: CIHR’s Team Grant: CEEHRC (Epigenetics)
`Genome Canada Genomics Innovation Network Technology
`Development International Review Committee
`National Center for Advancing Translational Sciences (NCATS), Special
`Emphasis Panel
`Genome Canada’s Membership to the Genomics Innovation Network
`and Core Operations Support Funds competition
`Genomics, Computational Biology and Technology (GCAT) study section
`Interdisciplinary Molecular Science and Training – Cell, Molecular, and
`Computational Biology study section
`Genomics, Computational Biology and Technology (GCAT) study section;
`Transformative research award review
`ISD study section, Bioengineering Sciences and Technologies
`NASA study section: “Differential Effects on Homozygous Twin
`Astronauts Associated with Differences in Exposure to Spaceflight
`Factors”
`ISD study section, Bioengineering Sciences and Technologies
`Partnerships for Enhanced Engagement in Research (PEER) Health, NICHD
`Terry Fox New Frontiers Program in Cancer Research
`Science & Technology Innovation Centers’ Renewal, Genome Canada
`Canada‐Japan CEEHRC Teams in Epigenetics of Stem Cells, CIHR, Co‐chair
`Chair: Team Grant: CEEHRC ‐ LOI committee.
`Chair: Epigenomics platform peer review committee, Canadian Institutes
`of Health research (CIHR)
`Chair: Epigenetics catalyst peer review committee, CIHR
`Ad hoc member of NIH Instrumentation and Systems Development (ISD)
`study section
`Science &Technology Innovation Center Competition Review: Genome
`Canada
`ATID Review: Genome Canada
`IDDRC P30 REVIEW, ZHD1‐MRG‐C (ID)
`Genomics, Computational Biology and technology study section, NIH
`DP3 Review, ZDK1 GRB‐N(01), NIDDK
`
`7
`
`
`2 ― Review panels:
`Mar 2016
`Jan 2016
`Jun 2015
`May 2015
`
`Mar 2015
`
`Nov 2014
`
`Oct 2014
`Jun 2014
`
`Mar 2014
`
`Feb 2014
`Jan 2014
`
`Dec 2013
`May 2013
`Apr 2013
`Apr 2013
`Jan 2013
`Aug 2012
`Feb 2012
`
`Feb 2012
`Sep 2011
`
`Feb 2011
`
`Nov 2010
`Mar 2010
`Oct 2009
`Jul 2009
`
`Page 7 of 18
`
`
`
`Applied Genomics Research in Bioproducts or Crops (ABC), Genome
`Canada
`NCI Structural Biophysics Laboratory Site Visit, NCI
`Technology Development Competition, Genome Canada
`Permanent member of NIH ISD study section
`Applied Emerging Technologies for Cancer Research, ZCA1 SRRB‐4 (M1),
`NCI
`Applied Emerging Technologies for Cancer Research, ZCA1 SRRB‐K (J1),
`NCI
`Innovative Technologies for the Molecular Analysis of Cancer, ZCA1 SRRB‐
`K (O1), NCI
`Applied Emerging Technologies for Cancer Research, ZCA1 SRRB‐9 (M1),
`NCI
`ISD study section [ZRG1 ISD (01)], NIBIB
`Emerging Technologies for Cancer Research, ZCA1 SRRB‐4 (J1), NCI
`ISD study section [ZRG1 ISD (01)], NIBIB
`Innovative Technologies for Cancer Research, ZCA1 SRRB‐3 (O1), NCI
`ISD study section [ZRG1 ISD (01)], NIBIB
`Innovative Molecular Analysis Technology, ZCA1 SRRB‐C (M2), NCI
`ISD study section, ZRG1 ISD (01), NIBIB
`Innovative Molecular Analysis Technology, ZCA1 SRRB‐C (01), NCI
`ISD study section, ZRG1 ISD (01), NIBIB
`Subcommittee E – Cancer Epidemiology, Prevention & Control study
`section, NCI‐E RPRB (X1), NCI
`ISD study section, ZRG1 ISD (01), NIBIB
`Genome Technology & Cytogenetics (GT&C) study section, ZRG1 GNM
`(90), NHGRI
`Atopic Dermatitis & Vaccinia Network; Clinical Studies Consortium study
`section [ZAI1 CL‐1 (C1), NIAID
`GT&C study section, ZRG1 GNM (90), NHGRI
`Genome study section, CSR‐GNM, NHGRI
`Center for Scientific Review – Special Emphasis Panel (CSR‐SEP) study
`section [ZRG1 SSS‐Y], NHGRI
`Bioengineering Research Partnership study section [ZRG1 SSS‐Y (02)],
`NHGRI
`CSR‐SEP study section [ZRG1 SSS‐Y (11) B], NHGRI
`Microbial Genome Project – study section, DOE
`CSR‐SEP SBIR/STTR study section [ZRG1 SSS‐Y (10)], NHGRI
`CSR‐SEP SBIR/STTR study section [ZRG1 SSS‐Y (01)], NHGRI
`CSR‐SEP SBIR/STTR study section [ZRG1 SSS‐Y (01)], NHGRI
`Technologies for Generation of Full‐Length Mammalian cDNA study
`section [CA99‐005], NCI
`CSR‐SEP SBIR/STTR study section [ZRG1 SSS‐Y (01)], NHGRI
`CSR‐SEP SBIR/STTR study section [ZRG1 SSS‐Y (01)], NHGRI
`SBIR/STTR Molecular Genetics study section [ZRG2 GNM O2B], NHGRI
`Biological & Physiological SEP study section [ZRG2 SSS‐Y (15)], NHGRI
`
` ― Professional societies:
`
`8
`
`Jan 2009
`
`Sep 2008
`Nov 2007
`2005‐2007
`Apr 2007
`
`Oct 2006
`
`Jun 2006
`
`Mar 2006
`
`Oct 2005
`Oct 2005
`Jul 2005
`Jun 2005
`Mar 2005
`Mar 2005
`Nov 2004
`Jul 2004
`Jul 2004
`Jun 2004
`
`Mar 2004
`Dec 2003
`
`Oct 2003
`
`Jul 2003
`Nov 2001
`Jul 2001
`
`Jul 2001
`
`Apr 2001
`Mar 2001
`Nov 2000
`Mar 2000
`Nov 1999
`Jul 1999
`
`Jul 1999
`Mar 1999
`Mar 1998
`Mar 1997
`
` 3
`
`Page 8 of 18
`
`
`
`1996‐to‐present
`2000‐to‐present
`2014‐to‐present
`
`American Association for the Advancement of Science
`American Chemical Society
`Texas Genetics Society
`
` 4
`
` ― Invited lectures, presentations, research seminars:
`Apr 2016
`Critical Path to TB Drug Regimens (CPRT) Workshop, Washington DC,
`Invited Speaker
`Advances in Next Generation Sequencing, Online, Keynote speaker
`ABRF‐ Satellite workshop, Palm Springs, CA; Invited Speaker
`American Society of Microbiology, San Francisco, CA;
`Invited Speaker
`Copenhagenomics, Copenhagen, Denmark, Invited Speaker
`Advances in Genome Biology & Technology, Marco Island, FL;
`Speaker
`Next‐Gen Sequencing Conference, Boston, MA; Keynote Speaker
`Texas Association for Clinical Laboratory Science (TACLS), Austin, TX;
`Invited Speaker
`Centre de Regulació Genòmica (CRG) Symposium, Barcelona Spain,
`Invited Speaker
`ACS Meeting, San Diego, CA; Invited Speaker
`Next Generation Sequencing Workshop, Lübeck University, Germany;
`Invited Speaker
`Genomics Automation Conference, Boston, MA; Invited Speaker
`Advances in Genome Biology & Technology, Marco Island, FL
`Invited Speaker
`Workshop on Genotyping‐Tissue Expression (GTEx) Resource, NIH
`Invited Participant
`International Conference on Genomics, Shenzhen, China;
`Invited Speaker
`IBC's Discovery‐2‐Diagnostics Conference, Philadelphia, PA
`Invited Chair & Speaker
`Advances in Genome Biology & Technology, Marco Island, FL
`Invited Speaker
`International Conference on Genomics, Hangzhou, China
`Invited Speaker
`Genomics of Hyperglycaemia, Elsinore, Denmark
`Invited Speaker
`Advances in Genome Biology & Technology, Marco Island, FL
`Invited Speaker
`5th Annual RECOMB Satellite meeting on DNA Sequencing Technologies
`and Computation, Stanford University; Invited Speaker
`Advances in Genome Biology & Technology, Marco Island, FL
`Invited Speaker
`Advances in Genome Biology & Technology, Marco Island, FL
`Invited Speaker
`BECON 2003 Symposium on Catalyzing Team Science, NIH
`Invited Speaker
`
`Oct 2007
`
`Sep 2007
`
`Feb 2007
`
`Oct 2006
`
`Sep 2006
`
`Feb 2006
`
`May 2005
`
`May 2015
`Mar 2013
`Jun 2012
`
`Jun 2012
`Feb 2012
`
`Apr 2011
`Apr 2011
`
`Oct 2010
`
`Jun 2010
`May 2010
`
`May 2010
`Feb 2009
`
`Jun 2008
`
`Feb 2005
`
`Feb 2004
`
`Jun 2003
`
`
`9
`
`Page 9 of 18
`
`
`
`Jan 2002
`
`Oct 2001
`
`Feb 2001
`
`May 2000
`
`Mar 1998
`
`Agriculture Program Research General Session, Texas A&M University
`Invited Speaker
`Genome sequencing and Analysis Conference XIII, San Diego, CA
`Invited Speaker
`Advances in Genome Biology & Technology, Marco Island, FL
`Invited Speaker
`Second Follow‐Up Workshop on Priority Setting for Mouse Genomics
`and Genetics Resources, NIH; Invited Participant
`Full‐Length cDNA Cloning: A Workshop on Problems and Solutions, The
`Banbury Center, Cold Spring Harbor; Invited Participant
`Workshop on Complete cDNA Sequencing, NIH; Invited Participant
`
`May 1997
`
`c. Publications
`1 ― Peer‐reviewed articles and reviews:
`1. Burgess K, Gibbs RA, Metzker ML, and Raghavachari R (1994) Synthesis of an Oxyamide
`Linked Nucleotide Dimer and Incorporation into Antisense Oligonucleotide Sequences, J.
`Chem. Soc., Chem Commun., 915‐916.
`2. Metzker ML, Raghavachari R, Richards S, Civitello A, Burgess K, and Gibbs RA (1994)
`Termination of DNA synthesis by novel 3’‐modified‐deoxyribonucleoside 5’‐triphosphates,
`Nucleic Acids Res. 22, 4259‐4267.
`3. Metzker ML, Allain KM, and Gibbs RA (1995) Accurate determination of DNA in agarose gels
`using the novel algorithm GelScann(1.0), Comput. Applic. Biosci. 11, 187‐194.
`4. Metzker ML, Lu J and Gibbs RA (1996) Electrophoretically Uniform Fluorescent Dyes for
`Automated DNA Sequencing, Science 271: 1420‐1422.
`5. Ansari‐Lari MA, Liu XM, Metzker ML, Rut AR and Gibbs RA (1997) The extent of genetic
`variation in the CCR5 gene. Nature Genet. 16: 221‐222.
`6. Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, Marknell T, Sandgren O, Forsman K, Holmgren
`G, Andreasson, S Vujic, M Bergen AAB, McGarty‐Dugan V, Figueroa D, Austin CP, Metzker
`ML, Caskey CT, and Wadelius C (1998) Identification of the gene responsible for Best
`macular dystrophy. Nature Genet. 19:241‐247.
`7. Metzker ML, Ansari‐Lari MA Liu XL, Holder DJ, and Gibbs RA (1998) Quantitation of Mixed‐
`Base Populations of HIV‐1 Variants by Automated DNA Sequencing with BODIPY Dye‐
`Labeled Primers. BioTechniques 25:446‐462.
`8. Hey PJ, Twells RCJ, Phillips MS, Nakagawa Y, Brown SD, Kawaguchi Y, Cox R, Xie G, Dugan V,
`Hammond H, Metzker ML, Todd JA, and Hess JF (1998) Cloning of a novel member of the
`low‐density lipoprotein receptor family. Gene 216:103‐111.
`9. Brown SD, Twells RCJ, Hey PJ, Cox RD, Levy ER, Soderman AR, Metzker ML, Caskey CT, Todd
`JA, and Hess JF (1998) Isolation and characterization of LRP6, a novel member of the low
`density lipoprotein receptor gene family. Biochem. Biophys. Res. Commun. 248:879‐888.
`10. Metzker ML, Raghavachari R, Burgess K, and Gibbs RA (1998) Elimination of residual natural
`nucleotides from 3'‐O‐modified‐dNTP syntheses by enzymatic Mop‐Up. BioTechniques
`25:814‐817.
`11. Muzny DM, Metzker ML, Bouck J, Gorrell JH, Ding Y, Maxim E, and Gibbs RA (1998) Using
`BODIPY Dye‐Primer Chemistry in Large‐Scale Sequencing. IEEE Engineering in Medicine and
`Biology 88‐93.
`12. Allikmets R, Seddon JM, Bernstein PS, Hutchinson A, Sharma S, Gerrard B, Li W, Metzker ML,
`Wadelius C, Caskey CT, Dean M, and Petrukhin K (1999) Rare variants of the best disease
`
`10
`
`Page 10 of 18
`
`
`
`gene in patients with age‐related macular degeneration and other maculopathies. Hum.
`Genet. 104: 449‐453.
`13. Bai C, Connolly B, Liu X, Hilliard CA, Galloway SM, Sandig V, Liu Q, Metzker ML, Austin CP,
`and Caskey CT (2000). Overexpression of a new secreted member of tumor necrosis factor
`receptor family in gastrointestinal tract tumors. Proc. Natl. Acad. Sci. USA 97:1230‐1235.
`14. Sandig V, Youil R, Bett AJ, Franlin LL, Oshima M, Maione D, Wang F, Metzker ML, Savino R,
`Caskey CT (2000) Optimization of the helper‐dependent adenovirus system for production
`and potency in vivo. Proc. Natl. Acad. Sci. USA. 97:1002‐1007.
`15. Bouck JB, Metzker ML, and Gibbs RA (2000) Shotgun sample sequence comparisons
`between mouse and human genomes. Nature Genet. 25:31‐3.
`16. Zhang K, Kniazeva M, Han M, Li W, Yu Z, Yang Z, Li Y, Metzker ML, Allikmets R, Zack DJ,
`Kakuk LE, Lagali PS, Wong PW, MacDonald IM, Sieving PA, Figueroa DJ, Austin CP, Gould RJ,
`Ayyagari R, and Petrukhin K (2001) A 5‐bp deletion in ELOVL4 is associated with two related
`forms of autosomal dominant macular dystrophy. Nature Genet. 27:89‐93.
`17. International Human Genome Sequencing Consortium: Baylor College of Medicine Human
`Genome Sequencing Center: Gibbs RA, Muzny DM Scherer SE, Bouck JB, Sodergren EJ,
`Worley KC, Rives CM, Gorrell JH, Metzker ML, Naylor SL, Kucherlapati RS, Nelson DL, and
`Weinstock GM (2001) Initial sequencing and analysis of the human genome. Nature
`409:860‐921.
`18. Twells RC, Metzker ML, Brown SD, Cox R, Garey C, Hammond H, Hey PJ, Levy E, Nakagawa Y,
`Philips MS, Todd JA, and Hess JF. (2001) The sequence and gene characterization of a 400‐
`kb candidate region for IDDM4 on chromosome 11q13. Genomics 72:231‐242.
`19. Dederich DA, Okwuonu G, Garner T, Denn A, Sutton A, Escotto M, Martindale A, Delgado O,
`Muzny DM, Gibbs RA and Metzker ML (2002) Glass Bead Purification of Plasmid Template
`DNA for High‐Throughput Sequencing of Mammalian Genomes. Nucleic Acids Res. 30:e32
`20. Metzker ML, Mindell DP, Ptak RG, Gibbs RA, and Hillis DM (2002) Molecular Evidence of
`HIV‐1 Transmission in a Louisiana Criminal Case. Proc. Natl. Acad. Sci. USA 99:14292‐14297.
`21. Twells RCJ, Mein CA, Payne F, Veijola R, Gilbey M, Bright M, Timms A, Nakagawa Y, Snook H,
`Nutland S, Rance HE, Carr P, Dudbridge F, Cordell HJ, Cooper J, Tuomilehto‐Wolf E,
`Tuomilehto J, Phillips M, Metzker M, Hess JF, Todd JA (2003) Linkage and association
`mapping of the LRP5 locus on chromosome 11q13 in type 1 diabetes. Human Genet.
`113:99‐105.
`22. Ueda H et al. (2003) Association of the T‐cell regulatory gene CTLA4 with susceptibility to
`autoimmune disease. Nature 423:506‐511.
`23. Thoresen LH, Jiao GS, Haaland WC, Metzker ML, and Burgess K (2003) Rigid, Conjugated,
`Fluoresceinated Thymidine Triphosphates: Syntheses and Polymerase Mediated
`Incorporation Into DNA. Chem. Eur. J. 9:4603‐4610.
`24. Twells RCJ, Mein CA, Phillips MS, Hess JF, Veijola R, Gilbey M, Bright M, Metzker ML, Lie BA,
`Kingsnorth A, Gregory E, Nakagawa Y, Snook H, Wang WYS, Masters J, Johnson G, Eaves I,
`Howson JMM, Clayton D, Cordell HJ, Nutland S, Rance H, Carr P and Todd JA (2003) Haplotype
`Structure, LD Blocks, and Uneven Recombination Within the LRP5 Gene. Genome Res.
`13:845‐855.
`25. Gibbs RA, Weinstock GM, Metzker ML et al. (2004) Genome sequence of the Brown Norway
`rat yields insights into mammalian evolution. Nature 428:493‐521.
`26. Richards S et al. (2005) Comparative genome sequencing of Drosophila pseudoobscura:
`chromosomal, gene, and cis‐element evolution. Genome Res. 15:1‐18.
`27. Ross MT et al. (2005) The DNA sequence of the human X chromosome. Nature 434:325‐337.
`
`11
`
`Page 11 of 18
`
`
`
`28. Lewis EK, Haaland WC, Nguyen F, Heller DA, Allen MJ, Macgregor RR, Berger CS, Willingham
`B, Burns LA, Scott GB, Kittrell C, Johnson BR, Curl RF, Metzker ML (2005) Color‐blind
`fluorescence detection for four‐color DNA sequencing Proc. Natl. Acad. Sci. USA 102:5346‐
`5351.
`29. Fernandez R, Zhang Y, Pai S, Metzker ML, Schumacher A (2005) l7Rn6 encodes a novel
`protein required for Clara cell function in mouse lung development. Genetics 172:389‐399.
`30. Metzker ML (2005) Emerging Technologies in DNA Sequencing. Genome Res. 15:1767‐1776.
`31. Scherer S et al. (2006) The Finished DNA Sequence of Human Chromosome 12. Nature 440
`346‐351.
`32. Muzny D et al. (2006) The DNA sequence, annotation and analysis of human chromosome 3.
`Nature 440:1194‐1198
`33. Jiao G‐S, Thoresen LH, KimTG, Haaland WC, Topp MR, Hochstrasser RM, Metzker ML, Burgess
`K (2006) Syntheses, photophysical properties, and applications of through‐bond energy
`transfer cassettes for multiplexing in biotechnology. Eur. J. Chem. 12:7816‐7826.
`34. Wu W, Stupi BP, Litosh VA, Mansouri D, Farley D, Morris S, Metzker S, Metzker ML (2007)
`Termination of DNA synthesis by N6‐alkylated, not 3’‐O‐alkylated, photocleavable
`2’‐deoxyadenosine triphosphates. Nucleic Acids Res. 35:6339‐49.
`35. Metzker, ML (2009) Sequencing in real time. Nature Biotechnol. 27:150‐151.
`36. Haaland WC, Scaduto DI, Maldonado, MR, Mansouri DL, Nalini R, Iyer D, Patel S, Guthikonda
`A, Hampe CS, Balasubramanyam A, Metzker ML. (2009) The “A‐β‐” subtype of Ketosis‐Prone
`Diabetes (KPD) is not predominantly a monogenic diabetic syndrome. Diabetes Care 32:873‐
`877.
`37. Church DM et al. (2009) Lineage‐specific biology revealed by a finished genome assembly of
`the mouse. PLoS Biol. 5:e1000112
`38. Metzker ML. (2010) Sequencing technologies ― the next genera(cid:415)on. Nature Rev. Genet.
`11:31‐46
`39. The 1000 Genomes Project Consortium. (2010) A map of human genome variation from
`population‐scale sequencing. Nature 467:1061‐73.
`40. Sudmant et al. Diversity of human copy number variation and multicopy genes. (2010)
`Science 330:641‐646.
`41. Scaduto DI, Brown JM, Haaland WC, Zwickl DJ, Hillis DM, Metzker ML. (2010) Source
`identification in two criminal cases using phylogenetic analysis of HIV‐1 DNA sequences.
`Proc Natl Acad Sci USA 107:21242‐21247.
`42. Litosh VA, Wu W, Stupi BP, Wa